Alicia González Quesada

Safety of Systemic Therapy for Psoriasis in Patients with Diabetes Mellitus: Data from the BIOBADADERM Prospective Cohort

Juan José Lluch‐Galcerá, José Manuel Carrascosa, Alicia González Quesada, Antonio Sahuquillo-Torralba et autres

Background and objective: Patients with psoriasis who also have diabetes mellitus (DM) may be vulnerable to diabetes-related adverse events (DM-AEs). Objective: to evaluate the incidence of DM-AEs associated with each systemic treatment used for patients with psoriasis and DM. Methods: Prospective cohort …

es (code pays fourni par la source)

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry

R.A.Q.U.E.L. RIVERA-DIAZ, Alicia González Quesada, Antonio Sahuquillo-Torralba, E. Daudén et autres

Interleukin 12/23 inhibitors (IL12/23i) and interleukin 17 and 23 inhibitors (IL17i and IL23i) represent the drug classes with the most favorable expectations for therapeutic response. However, the introduction of biosimilars has led many centers, for reasons of efficiency, to prioritize tumor necrosis …

es (code pays fourni par la source)

Characteristics, Treatment, and Safety Profile of Patients With Atopic Dermatitis According to Eligibility for Randomized Clinical Trials: An Analysis From the Spanish Atopic Dermatitis Registry (BIOBADATOP)

M Munera-Campos, Alicia González Quesada, Milena Arias, Miguel Antonio Lasheras‐Pérez et autres

BACKGROUND: Randomized clinical trials (RCTs) supporting advanced treatments for atopic dermatitis (AD) involve highly selected patients, limiting their generalizability. OBJECTIVE: To determine the proportion of adults on advanced systemic therapy for AD in clinical practice who are underrepresented in RCTs and compare …

es (code pays fourni par la source)

Patient Burden And Impact Of Moderate-to-Severe Atopic Dermatitis In the Spanish Healthcare System: The APOLO Cross-Sectional Study

P. de la Cueva Dobao, Laia Curto‐Barredo, J.F. Silvestre, Pedro Herranz et autres

INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory condition associated with a significant physical, psychological, and economic burden. This study aimed to determine the multidimensional impact of AD on patients and the Spanish healthcare system. METHODS: The present multicenter descriptive cross-sectional study …

es (code pays fourni par la source)

Ocrelizumab‐induced psoriasiform dermatitis: Case reports and review of the literature

Natalia Naranjo Guerrero, Alicia González Quesada, Ángela García Miñarro, Ana Begoña Paredes Pérez et autres

Abstract Ocrelizumab (OCR) is a humanized anti‐CD20 monoclonal antibody approved for treating multiple sclerosis. We present three patients who developed psoriasiform dermatitis (PsD) during OCR treatment and a review of the cases published to date. We hereby report the first exclusive fingernail …

es (code pays fourni par la source)

Measurement of the Psychological Impact of Psoriasis on Patients Receiving Systemic Treatment

M.B. Madrid Álvarez, G. Carretero Hernández, Alicia González Quesada, Josune Martín

The negative impact of psoriasis on patient quality of life can be as important as the physical consequences of the disease. We could assume that clearance of the disease would also lead to an improvement in its psychosocial impact. The present study …

es (code pays fourni par la source)

Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016

G. Carretero Hernández, Carlos Ferrándiz, Esteban Daudén Tello, Francisco Gómez‐García et autres

Biologic drugs are usually prescribed as second-line treatment for psoriasis, that is, after the patient has first been treated with a conventional psoriasis drug. There are, however, cases where, depending on the characteristics of the patient or the judgement of the physician, …

es (code pays fourni par la source)

Medición del impacto psicológico en pacientes con psoriasis en tratamiento sistémico

M.B. Madrid Álvarez, G. Carretero Hernández, Alicia González Quesada, Josune Martín

es (code pays fourni par la source)

Descripción de los pacientes que reciben biológicos como primer tratamiento sistémico en el registro BIOBADADERM durante el periodo 2008-2016

G. Carretero Hernández, Carlos Ferrándiz, Esteban Daudén Tello, Francisco Gómez‐García et autres

es (code pays fourni par la source)

Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches

Carlos González‐Herrada, Sara Rodríguez‐Martín, Lucía Cachafeiro, Victoria Lerma et autres

es (code pays fourni par la source)

Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients

Camila Cabello Zurita, Mercè Grau‐Pérez, C. Hernández-Fernández, Alicia González Quesada et autres

BACKGROUND: Methotrexate (MTX), a traditional antipsoriatic drug, is very frequently used either as monotherapy or in combination with other systemic drugs. OBJECTIVES: To assess the effectiveness and safety of MTX in psoriasis in usual clinical practice. METHODS: We conducted a retrospective study. …

es (code pays fourni par la source)

Novedades en la fisiopatología de los pénfigos

Anselmo Javier Gómez Duaso, Alicia González Quesada

es (code pays fourni par la source)